secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alkermes plc. (ALKS)
CIK:        0001520262
Form:       8-K
Filed at:   2022-11-02T23:59:59+00:00
Accession:  0000950170-22-020969
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alkermes reports Q3 GAAP loss of $0.39/share; plans to separate oncology business
--------------------------------------------------------------------------------

- Q3 total revenues $252.4M; net loss $64.0M; GAAP EPS -$0.39, non-GAAP EPS $0.02.
- Proprietary product net sales $199.4M: VIVITROL $96.5M (+9% YoY), ARISTADA $75.7M (+10%), LYBALVI $27.1M.
- Board approved exploration of separating oncology business into independent public company; expected completion H2 2023.
- Updated FY2022 guidance: total revenue $1.07B-$1.12B, non-GAAP EPS $0.15-$0.33; LYBALVI outlook raised to $88-$95M.
- One-time AMPYRA royalty reversal of ~$21.5M due to arbitration award.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1520262/000095017022020969/0000950170-22-020969-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1520262/000095017022020969/alks-20221102.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-020969

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer